커뮤니티

인터넷 바다이야기 95.rnm453.top 바로가기 도그하우스 하는법, 바다이야기 릴게임

슬롯게임 무료 87.rnm453.top 알라딘릴게임장

야마토게임장주소 73.rnm453.top 릴짱

오션파라다이스 49.rnm453.top 온라인 손오공 릴게임

바다이야기게임다운 0.rnm453.top 카지노 잭팟

온라인 야마토 게임 78.rnm453.top 온라인야마토릴게임

무료충전바다이야기 84.rnm453.top 바다신2 게임

잭팟게임 39.rnm453.top 인터넷바다이야기

릴게임 먹튀보증 32.rnm453.top 강원랜드 슬롯머신 확률 공개

프라그마틱 무료게임 83.rnm453.top 슬롯머신 무료체험

바다이야기 2화 97.rnm453.top 온라인 슬롯 게임 추천

오션파라다이스7하는곳 야마토온라인주소 오션파라 다이스게임 하는법 슬롯머신 프로그램 한게임바둑이추천 오션슬롯 주소 야마토3게임 적토마게임 백경게임다운로드 창원경륜경륜장 인터넷빠찡꼬 바다신게임 모바알바다이야기 슬롯무료체험 모바일릴게임 종류 바다이야기꽁머니환전윈윈 온라인슬롯머신 오션파라다이스릴게임 야마토게임 다운로드 릴게임임대 바다이야기 조작 신야마토 신천지게임 하는곳 다빈치릴게임다운로드 오리지날바다 오션 오리지날게임 바다이야기2화 pc야마토게임 야마토 게임방법 오션슬롯주소 오리지날바다 무료 메가 슬롯 머신 블랙잭추천 무료충전 바다이야기 백경게임 하는곳주소 파칭코게임 소액 슬롯 추천 야마토2 바다이야기게임2018 바다신2영상 바다이야기게임하는곳 강원랜드 잭팟 확률 신오션파라다이스 현금게임 야마토무료게임 바다이야기 먹튀 신고 몰게임 바다이야기오리지널 온라인삼국지 오토 무료인터넷게임 오리지날바다 정글북 릴게임먹튀검증 슬롯 무료체험 바다이야기 pc버전 다운 백경다운로드 바다이야기예시 황금성슬롯 슬롯머신 무료체험 프라그마틱 슬롯 모바일황금성 알라딘먹튀 오리지널황금성 인터넷야마토게임 릴황금성 바다 슬롯 먹튀 슬롯머신 확률 무료바다이야기 릴게임 온라인 씨엔조이 슬롯 검증사이트 바다이야기 황금고래 바다이야기 확률 무료충전바다이야기 야마토3다운로드게임사이트 체리마스터 릴게임뜻 릴게임공략법 보물섬릴게임 상품권릴게임 신 천지 게임 오리 지날 바다 오리지널 바다이야기 바다신 게임 릴게임한국 신천지게임하는방법 바다슬롯먹튀 온라인 황금성 팡멀티릴게임 88오락실릴게임 황금성예시 온라인릴게임예시 슬롯머신추천 야마토게임사이트 릴게임설치 야마토2 pc버전 바다이야기상어 사이다쿨 릴게임 황금성릴게임 황금성게임어플 슬롯무료게임 신천기릴게임 양귀비 릴게임 바다이야기 하는 법 온라인릴게임 먹튀 검증 우주전함 야마토 먹튀 백경게임 하는곳주소 알라딘설명 무료인터넷게임 황금성잭팟 스위피릴게임 프라그마틱무료메타2 릴게임알라딘주소 알라딘 스핀모바게임랜드 최신인터넷게임 우주전함 야마토게임 모바일게임 오리지날릴게임 슬롯커뮤니티 바다이야기시즌7 프라그마틱 슬롯 종류 온라인야마토 무료 황금성게임 종합 릴게임 This article was released as Pharm Edaily Premium Content on August 29, 2025, at 10:00 AM.


[Seungkwon Kim, Edaily Reporter] On Aug. 28, South Korea’s pharmaceutical, biotech and health care stocks rallied, led by companies that either secured presentations at major international conferences or posted encouraging clinical outcomes.
Hyundai ADM Hits Limit바다이야기 릴게임
on U.S. Cancer Conference News; Hyundai Bioscience Jumps
Hyundai Bioscience and Hyundai ADM jumped together after news that an abstract was accepted for presentation at a top-tier conferenc오션파라다이스3
e. NeoImmuneTech advanced on efficacy signals from a primate study, and Protia rose on expectations of continued revenue growth after a recent swing to profit.
Hyundai ADM surged to the exch세보엠이씨 주식
ange’s daily limit early and closed up 29.8% at 3,000 won, according to MPDOCTOR by KG Zeroin (formerly Market Point). The gain followed word that the company’s abstract on its drug candidate Penetriusk텔레콤 주식
m was accepted for a poster at AACR 2025, a tri-society meeting jointly hosted by the American Association for Cancer Research (AACR), the U.S. National Cancer Institute (NCI) and the European Organis오션파라다이스7
ation for Research and Treatment of Cancer (EORTC).



Hyundai ADM share-price trend (data: KG Zeroin)



The accepted abstract, titled “Disrupting the oncobiosphere: CAF-targeting therapy with Penetrium reverses pseudo-resistance in tumors,” posits that structural barriers in the tumor microenvironment stiffened extracellular matrix and related factors rather than genetic resistance alone, underlie treatment failure. Penetrium is a reformulation of the anthelmintic niclosamide designed to improve bioavailability. By selectively dismantling the rigidified tumor microenvironment while sparing normal fibroblasts, the candidate aims to reopen tumors to existing chemotherapies and immunotherapies, potentially benefiting patients with metastatic and treatment resistant disease. “This abstract acceptance internationally recognizes a paradigm that could address fundamental limits of current cancer therapy,” CEO Cho Won-dong said, adding that Hyundai ADM will work with parent Hyundai Bioscience to move Penetrium quickly into global development and commercialization.

Hyundai Bioscience also climbed, finishing up 25% at 6,660 won. Beyond the affiliate’s abstract news, investors cited expectations for TPOXX (tecovirimat) supply in smallpox and mpox, alongside the company’s pipeline momentum. The timing drew added attention: Shortly after Nature Communications published a clinical paper on the company’s broad spectrum antiviral candidate Xafty (CP COV03), Hyundai Bioscience said it received an official invitation from the U.S. Rapid Response Partnership Vehicle (RRPV).
Recently in Magok, Seoul, Hyundai Bioscience President Bae Byung-joon met Naoki Shinahora, CEO of Japan Biotechno Pharma Co., Ltd. (JBP), to discuss securing Korean rights and building a supply chain for TPOXX. JBP holds Japanese commercialization rights to TPOXX developed by U.S.-based SIGA Technologies and supplies it to Japan’s government.
Developed under the U.S. Biomedical Advanced Research and Development Authority’s Project BioShield, TPOXX is an approved, targeted medical countermeasure in the United States, Europe and Japan and is stockpiled by governments. South Korea is also weighing procurement as part of biodefense and pandemic preparedness. The talks underscore that Xafty (pipeline) and TPOXX (approved) are distinct strategic assets: TPOXX can be supplied immediately to government stockpile markets, while Xafty advances as a broad antiviral candidate. Hyundai Bioscience said the discussions reflect an expanding partner network spanning SIGA Technologies in the United States, JBP in Japan and the Drugs for Neglected Diseases initiative (DNDi).
NeoImmuneTech, Protia Surge...Why
NeoImmuneTech rose 17% to 1,096 won after reporting survival benefits in a nonhuman primate model of acute radiation syndrome (ARS) for its T cell amplifier NT I7. ARS is caused by short term, high dose radiation exposure that can devastate the immune system and bone marrow. Under the U.S. Food and Drug Administration’s “Animal Rule,” NT I7 is being developed as a lymphocyte restoring ARS therapy, a pathway that allows approval based on adequate animal data when human trials are unethical.



Protia Share-Price Trend (data: KG Zeroin)



According to the company, the high dose NT I7 group achieved a 60 day survival rate that was 43 percentage points higher than the irradiation only placebo control, a magnitude that is similar to or above the 38 43 percentage point improvements reported for FDA approved ARS therapies. Surviving animals also showed rapid T cell recovery, another Animal Rule criterion. Building on its first primate study, NeoImmuneTech said it will consult the FDA and proceed to a follow on study, again tracking 60 day survival and lymphocyte counts. “If NT I7 secures FDA approval as an ARS therapy, partnership and market opportunities across multiple immunologic unmet needs could expand materially,” a company official said, noting NT I7’s previously reported anti tumor activity in combination with CAR T therapies.

Protia climbed 14% to 5,190 won. The company’s results have been trending higher: First half revenue came to 6.54 billion won, up 41.5% year over year, and operating profit rose to 1.46 billion won from 400 million won a year earlier. Protia expects strong second half growth centered on allergy diagnostics, as its premium “PROTIA Allergy Q 192D” panel covering 176 allergens, including drug and chemical antigens enters full scale supply. The company also anticipates sharply higher demand for veterinary diagnostics in China, new sales of veterinary allergy tests in Brazil and a first launch in India of an antibiotic susceptibility test that uses an electrical capacitance measurement method.
김승권 (peace@edaily.co.kr)

추천0 비추천0